Screener
Alnylam Pharmaceuticals ALNY Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other (expense) income: | ||||
| Interest expense | (82,051) | (61,456) | (151,337) | (119,765) |
| Interest income | 28,143 | 27,486 | 54,741 | 56,159 |
| Other income (expense), net | 273 | 8,860 | (4,022) | 18,051 |
| Total other expense, net | (53,635) | (25,110) | (100,618) | (45,555) |
| Income (loss) before income taxes | 177,806 | (41,309) | 399,459 | (43,677) |
| Provision for income taxes | (13,312) | (30,919) | (28,974) | (46,802) |
| Net income (loss) | $164,494 | $(72,228) | $370,485 | $(90,479) |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's other income, net (note 6)?
- Alnylam Pharmaceuticals (ALNY) reported other income, net (note 6) of $273K in Q2 2026.
- How has Alnylam Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Alnylam Pharmaceuticals's other income, net (note 6) increased by 104.3% year-over-year, from -$6.4M to $273K.
- What is the long-term trend for Alnylam Pharmaceuticals's other income, net (note 6)?
- Over 3 years (2021 to 2025), Alnylam Pharmaceuticals's other income, net (note 6) has grown at a 36.4% compound annual growth rate (CAGR), from -$2.05M to $5.2M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Alnylam Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude